New research at The University of Texas MD Anderson Cancer Center has unearthed a previously unknown phenomenon: Key regulatory molecules are decreased when deprived of oxygen which leads to increased cancer progression in vitro and in vivo.
Federal Express® and UPS® are no match for the human body when it comes to distribution. There exists in cancer biology an impressive packaging and delivery system that influences whether your body will develop cancer or not.
Exosomes, tiny, virus-sized particles released by cancer cells, can bioengineer micro-RNA (miRNA) molecules resulting in tumor growth. They do so with the help of proteins, such as one named Dicer.
“Two leaders at The University of Texas MD Anderson Cancer Center have been elected to the Institute of Medicine (IOM) of the National Academies in recognition of their contributions to medical science and health care.
Removal of the entire lobe of lung may offer patients with early-stage lung cancer better overall survival when compared with a partial resection, and stereotactic ablative radiotherapy (SABR) may offer the same survival benefit as a lobectomy for some patients, according to a study from The University of Texas MD Anderson Cancer Center.
The study led by scientists at The University of Texas MD Anderson Cancer Center addresses the challenge of what scientists call genomic heterogeneity, the presence of many different variations that drive tumor formation, growth and progression, and likely complicate the choice and potential efficacy of therapy.
Bristol-Myers Squibb Company (NYSE: BMY) and The University of Texas MD Anderson Cancer Center today announced a novel clinical research collaboration to evaluate multiple immunotherapies, including Opdivo (nivolumab), Yervoy (ipilimumab) and three early-stage clinical immuno-oncology assets from Bristol-Myers Squibb, as potential treatment options for acute and chronic leukemia as well as other hematologic malignancies.
The Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy at The University of Texas MD Anderson Cancer Center has launched a fellowship program to advance the discovery and delivery of effective and accessible personalized cancer treatments.
MD Anderson is extending its cancer prevention efforts by teaming up with anti-tobacco programs run by the University of Houston and Austin Travis County Integral Care (ATCIC).
Researchers at The University of Texas MD Anderson Cancer Center have identified a biomarker living next door to the KLK3 gene that can predict which GS7 prostate cancer patients will have a more aggressive form of cancer.
ExxonMobil today announced a $10 million grant to The University of Texas MD Anderson Cancer Center’s Moon Shots Program, an unprecedented, comprehensive initiative to significantly reduce deaths from cancer.
A study led by Gordon Mills, M.D., Ph.D., professor and chair of Systems Biology at The University of Texas MD Anderson Cancer Center with Lydia Cheung, Ph.D. as the first author, points to cellular mutations in the gene PIK3R1 which activate ERK and JNK, thus allowing tumor growth.
Scientists at The University of Texas MD Anderson Cancer Center have found that cancer cells traveling to other sites have different energy needs from their “stay-at-home” siblings which continue to proliferate at the original tumor site.
Dominica Anderson, a nursing assistant at The University of Texas MD Anderson Cancer Center, is the 2014 recipient of the Julie and Ben Rogers Award for Excellence in Patient Care.
Stephen Hahn, M.D., an international leader in the field of radiation oncology has been named as the division head of radiation oncology and chair of the department of radiation oncology at The University of Texas MD Anderson Cancer Center. He joins MD Anderson on Jan. 1.
The Broach Foundation for Brain Cancer Research has made a $5 million commitment to support glioblastoma multiforme research at The University of Texas MD Anderson Cancer Center.
A new breast cancer vaccine candidate, (GP2), provides further evidence of the potential of immunotherapy in preventing disease recurrence.
When factoring in what is now known about breast cancer biology and heterogeneity, breast conserving therapy (BCT) may offer a greater survival benefit over mastectomy to women with early stage, hormone-receptor positive disease, according to research from The University of Texas MD Anderson Cancer Center.
Despite its acceptance as standard of care for early stage breast cancer almost 25 years ago, barriers still exist that preclude patients from receiving breast conserving therapy (BCT), with some still opting for a mastectomy, according to research from The University of Texas MD Anderson Cancer Center.
Scientists at The University of Texas MD Anderson Cancer Center in Houston have identified genetic mutations in endometrioid endometrial carcinoma (EEC), the most common form of this cancer of the uterine lining.
A gene crucial for brain and heart development may also be associated with sudden unexplained death in epilepsy (SUDEP), the most common cause of early mortality in epilepsy patients.
Memorial Hermann Health System and The University of Texas MD Anderson Cancer Center today announced a new partnership to provide a new level of specialized breast screening at a network of community breast care centers in the greater Houston area.
The University of Texas MD Anderson Cancer Center announced today an alliance with Cambridge, MA-based Foundation Medicine. The teams are opening a randomized-controlled trial to determine whether targeted therapies selected based on tumor molecular profiling compared with treatment not selected on this basis results in longer progression-free survival in patients with advanced disease.
Healthy men participating in the Prostate Cancer Prevention Trial who actively participate in all steps of the clinical trial are most likely to undergo a biopsy, according to a study published in Cancer Epidemiology, Biomarkers and Prevention – a journal of the American Association for Cancer Research.
Effective new drugs and screening would make hepatitis C a rare disease by 2036, according to a computer simulation conducted by The University of Texas MD Anderson Cancer Center and the University of Pittsburgh Graduate School of Public Health.
One protein with the even more out-there name of ZEB1 (zinc finger E-box binding homeobox 1), is now thought to keep breast cancer cells from being successfully treated with radiation therapy, according to a study at The University of Texas MD Anderson Cancer Center in Houston.
The University of Texas MD Anderson Cancer Center has announced a partnership with Hospital Israelita Albert Einstein (HIAE) to pioneer multidisciplinary patient care in Brazil and advance MD Anderson’s mission to eliminate cancer globally.
Just as no two people possess the same genetic makeup, a recent study has shown that no two single tumor cells in breast cancer patients have an identical genome. In fact, depending on the tumor cell, they grow at dramatically different speeds, according to a study led by Nicholas Navin, Ph.D., assistant professor in the Department of Genetics at The University of Texas M.D. Anderson Cancer Center in Houston.
The University of Texas MD Anderson Cancer Center is pleased to announce that one of the world’s preeminent experts in breast cancer research and treatment, V. Craig Jordan, Ph.D., will join the institution’s efforts to end cancer. Jordan is considered the “Father of Tamoxifen,” the groundbreaking therapeutic drug that has saved countless lives.
New research from The University of Texas MD Anderson Cancer Center is shedding light on the important role a diagnosing urologist plays in whether older men with low-risk prostate cancer receive treatment for their disease, and if so, the type of treatment they receive as a result.
Circulating tumor cells spread ovarian cancer through the bloodstream, homing in on a sheath of abdominal fatty tissue where it can grow and metastasize to other organs, scientists at The University of Texas MD Anderson Cancer Center report in Cancer Cell.
A study at The University of Texas MD Anderson Cancer Center used the Sleeping Beauty gene transfer system to modify T cells in hopes of fighting major life-threatening infections caused by invasive Aspergillus fungus. Results of the study appear in today’s issue of the Proceedings of the National Academy of Sciences (PNAS).
The results indicated that the science of pseudogene expression analysis may very well play a key role in explaining how cancer occurs by helping medical experts in the discovery of new biomarkers. The study’s findings appear in today’s issue of Nature Communications.
The first Tang Prize for Biopharmaceutical Science has been awarded to Jim Allison, Ph.D., chair of Immunology at The University of Texas MD Anderson Cancer Center and Tasuku Honjo, M.D., Ph.D., of Japan’s Kyoto University for their research leading to cancer immunotherapy.
Pancreatic cancer tumors addicted to mutant Kras signaling for their growth and progression have a ready-made substitute to tap if they’re ever forced to go cold-turkey on the mutant oncogene, scientists at The University of Texas MD Anderson Cancer Center report in the journal Cell.
African American women with early stage, invasive breast cancer were 12 percent less likely than Caucasian women with the same diagnosis to receive a minimally invasive technique, axillary sentinel lymph node (SLN) biopsy, even as the procedure had become the standard of surgical practice, according to research from The University of Texas MD Anderson Cancer Center.
Needle biopsy, the standard of care radiological procedure for diagnosing breast cancer, is underused with too many patients undergoing the more invasive, excisional biopsy to detect their disease, according to research from The University of Texas MD Anderson Cancer Center.
As the American Society of Clinical Oncology (ASCO) celebrates its 50th anniversary, the organization named former MD Anderson president John Mendelsohn, M.D., Waun Ki Hong, M.D., and Gabriel Hortobagyi, M.D. to its list of luminaries.
In an aggressive disease known for poor response rates, researchers from The University of Texas MD Anderson Cancer Center found patients with advanced colorectal cancer responded well to a combination therapy of the drugs vermurafenib, cetuximab and irinotecan.
Women with metastatic breast cancer to the bone may be able to receive bisphosphonates, the bone-targeting class of drugs like zoledronic acid, less often after the first year of monthly administration. With that practice change, women may also reduce their risk of serious side effects, according to a study led by researchers at The University of Texas MD Anderson Cancer Center.
Researchers at The University of Texas MD Anderson Cancer Center and other institutions have applied a newly developed software tool to identify genetic mutations that contribute to a person’s increased risk for developing common, complex diseases, such as cancer.
Dr. Condoleezza Rice was the honoree of The University of Texas MD Anderson Cancer Center’s A Conversation With a Living Legend®, Wednesday, May 21 at the Westin Galleria. Significantly surpassing all past years’ fundraising totals for the Houston event, it attracted 930 guests and raised more than $1,031,000 for MD Anderson’s Moon Shots Program, an unprecedented, comprehensive effort to significantly reduce cancer deaths and to transform cancer care, initially focusing on eight cancers. Proceeds will be used specifically to support the Prostate Cancer Moon Shot.
Oncologists now have a new understanding of the toxicity levels of specific chemotherapy regimens used for women with early stage breast cancer, according to research from The University of Texas MD Anderson Cancer Center.
In a small study, researchers from The University of Texas MD Anderson Cancer Center found that 93 percent of head and neck cancer patients treated with multi-field optimization intensity modulated proton therapy (MFO-IMPT) were cancer-free 28 months after treatment.
Myeloid-derived suppressor cells (MDSCs), are found abundantly in the microenvironment around tumors. They interfere with immune response, promoting cancer progression. MD Anderson researchers have found a potential route to target MDSCs
Fibrous tissue long suspected of making pancreatic cancer worse actually supports an immune attack that slows tumor progression but cannot overcome it, scientists at The University of Texas MD Anderson Cancer Center report in the journal Cancer Cell.
In an effort to combat lung cancer and other serious diseases, The University of Texas MD Anderson Cancer Center will adopt a tobacco-free hiring policy beginning, Jan. 1, 2015.
The University of Texas MD Anderson Cancer Center this week honored 16 junior faculty members who are expected to become some of America's future cancer leaders. The faculty members are the first R. Lee Clark Fellow award winners. The new award was established to recognize outstanding work by junior faculty members and to help support their future efforts.
A tumor-suppressing protein acts as a dimmer switch to dial down gene expression. It does this by reading a chemical message attached to another protein that’s tightly intertwined with DNA, a team led by scientists at The University of Texas MD Anderson Cancer Center reported at the AACR Annual Meeting 2014.
Agreement finalizes institution’s program with large pharmaceutical companies
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right